HealthQuill Daiichi Sankyo
https://www.merck.com/news/daiichi-sankyo-and-merck-enter-into-global-development-and-commercialization-agreement-for-mk-6070/
Drugs Health Pharma

Daiichi Sankyo to pay Merck $170 million for cancer test drug rights

Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.

Read More
Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered at a “fair price.”
Drugs Health Pharma

UK watchdog blocks AstraZeneca, Daiichi’s breast cancer drug

Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered.

Read More
The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat a type of lung cancer.
Drugs Health Pharma

FDA rejects Daiichi, Merck, antibody-drug conjugate application

The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat.

Read More
AstraZeneca, Daiichi’s breast cancer drug trial results show improvement in progression-free survival
Drugs Health Pharma

AstraZeneca, Daiichi’s breast cancer drug trials show rise in survival

HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.

Read More